Boehringer Ingelheim has received approval for an update of the summary of product characteristics (SmPC) for Viramune (nevirapine) as a treatment for patients with HIV.
The company said that the European Commission’s decision came after a positive recommendation from the CHMP.
Viramune’s SmPC has been updated to show that clinical studies have indicated the treatment is linked to an increase in HDL cholesterol, as well as an overall improvement in the total proportion of HDL cholesterol within the body.
Dr Manfred Haehl, Senior Vice President of Medicine at Boehringer Ingelheim, stated that the firm is “very satisfied” with the Commission’s decision.
“Physicians treating patients with HIV need to have a range of treatment options available so they can tailor the therapy to the individual patient’s need and response,” he added.